Increase of telomerase activity and hTERT expression in myelodysplastic syndromes

Cancer Biology and Therapy

Volumn 8, Issue 10, 2009, Pages 883-889

  Briatore, Federica ^a   Barrera, Giuseppina ^a   Pizzimenti, Stefania ^a   Toaldo, Cristina ^a   Della Casa, Chiara ^a   Laurora, Stefano ^a   Pettazzoni, Piergiorgio ^a   Dianzani, Mario Umberto ^a   Ferrero, Dario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

hTERT; Myelodysplastic syndromes; Telomerase activity; Transcription factors

Indexed keywords

MYC PROTEIN; PROTEIN MAD1; PROTEIN P53; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; EARLY DIAGNOSIS; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; ONCOGENE C MYC; PROTEIN EXPRESSION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; RNA, MESSENGER; TELOMERASE; TRANSCRIPTION FACTORS;

EID: 68049129840     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.10.8130     Document Type: Article

References (47)

1. Greider CW. Telomere length regulation. Annu Rev Biochem 1996; 65:337-65.
2. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol 1972; 239:197-201.
3. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999; 96:14276-81.
4. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-5.
5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787-91.
6. Roth A, Vercauteren S, Sutherland HJ, Lansdorp PM. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003; 17:2410-7.
7. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. Br J Haematol 1998; 102:1367-75.
8. Ohyashiki JH, Ohyashiki K, Iwama H, Hayashi S, Toyama K, Shay JW. Clinical implications of telomerase activity levels in acute leukemia. Clin Cancer Res 1997; 3:619-25.
9. Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS, et al. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 2005; 79:267-73.
10. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 2005; 68:779-86.
11. Aul C, Germing U, Gattermann N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 1998; 22:93-100.
12. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2004; 1:297-317.
13. Mufti GJ. Pathobiology, classification and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17:543-57.
14. Hofmann WK, Ottmann OG, Ganser A, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol 1996; 33:177-85.
15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079-88.
16. Gurkan E, Tanriverdi K, Baslamisli F. Telomerase activity in myelodysplastic syndromes. Leuk Res 2005; 29:1131-9.
17. Bock O, Serinsoz E, Schlue J, Kreipe H. Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res 2004; 28:457-60.
18. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002; 66:407-25.
19. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59:551-7.
20. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, et al. p53-dependent downregulation of telomerase is mediated by p21waf1. J Biol Chem 2004; 279:50976-85.
21. Qian J, Chen ZX, Cen JN, Wang W. Preliminary study on the gene expression profiles of bone marrow mononuclear cells from patients with myelo-dysplastic syndrome by using cDNA microarray. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004; 12:595-600.
22. Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by upregulation of antiapoptotic proteins. Blood 2007; 109:23399-405.
23. Verdiman JW, Harris NL, Brunning D. The World Health Organization (WHO) classification of myeloid neoplasms. Blood 2002; 100:2292-302.
24. Pizzimenti S, Barrera G, Dianzani MU, Brusselbach S. Inhibition of D1, D2 and A-cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal. Free Radic Biol Med 1999; 26:1578-86.
25. Yajima T, Yagihashi A, Kameshima H, Furuya D, Kobayashi D, Hirata K, et al. Establishment of quantitative reverse transcription - polymerase chain reaction assays for human telomerase-associated genes. Clin Chim Acta 2000; 290:117-27.
26. Barrera G, Pizzimenti S, Serra A, Fazio VM, Canuto RA, Dianzani MU. Effect of bioactive aldehydes on cell proliferation and c-myc expression in HL-60 human leukemic cells. Cancer Detect Prev 2000; 24:244-51.
27. Chaffin CL, Brogan RS, Stouffer RL, VandeVoort CA. Dynamics of Myc/Max/Mad expression during luteinization of primate granulosa cells "in vitro": association with periovulatory proliferation. Endocrinology 2003; 144:1249-56.
28. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277:21843-50.
29. Gelmini S, Caldini A, Becherini L, Capaccioli S, Pazzagli M, Orlando C. Rapid, quantitative nonisotopic assay for telomerase activity in human tumors. Clin Chem 1998; 44:2133-8.
30. Tatematsu K, Nakayama J, Danbara M, Shinoia S, Sato H, Omine M, et al. A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias. Oncogene 1996; 13:2265-74.
31. Engelhardt M, Wasch R, Guo Y. Telomeres and telomerase in normal and leukemic hematopoietic cells. Leuk Res 2004; 28:1001-4.
32. Ohyashiki K, Iwama H, Yahata N, Tauchi T, Kawakubo K, Shimamoto T, et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 2001; 42:291-9.
33. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85:2315-20.
34. Ohyashiki JH, Hayashi S, Yahata N, Iwama H, Ando K, Tauchi T, et al. Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. Int J Oncol 2001; 18:593-8.
35. Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006; 20:671-9.
36. Ohshima K, Karube K, Shimazaki K, Kamma H, Suzumiya J, Hamasaki M, et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003; 44:1339-46.
37. Oh S, Song YH, Kim UJ, Yim J, Kim TK. In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem Biophys Res Commun 1999; 263:361-5.
38. Gunes C, Lichtsteiner S, Vasserot AP, Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000; 60:2116-21.
39. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Bjorkholm M, et al. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res 2007; 67:2626-31.
40. Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, Brown M, et al. Transcriptional activation of hTERT through the NFkappaB pathway in HTLV-I-transformed cells. Blood 2004; 104:2523-31.
41. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88:4275-87.
42. Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene 2003; 22:9007-21.
43. Hurlin PJ, Huang J. The MAX-interacting transcription factor network. Semin Cancer Biol 2006; 16:265-74.
44. Qian J, Chen Z, Wang W, Cen J, Xue Y. Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome. Oncol Rep 2005; 14:1189-97.
45. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome- derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 2000; 102:115-23.
46. Invernizzi R, Pecci A, Bellotti L, Ascari E. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma 2001; 42:481-9.
47. Sekers MA. The myelodysplastic syndromes. Expert Opin Biol Ther 2007; 7:369-77.